Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 224.03M P/E - EPS this Y 57.10% Ern Qtrly Grth -47.40%
Income -25.09M Forward P/E -9.21 EPS next Y 250.00% 50D Avg Chg -9.00%
Sales 115.78M PEG -0.26 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book N/A EPS next 5Y 70.00% 52W High Chg -37.00%
Recommedations 2.50 Quick Ratio 1.64 Shares Outstanding 175.40M 52W Low Chg 93.00%
Insider Own 2.11% ROA -10.73% Shares Float 146.96M Beta 0.98
Inst Own 61.39% ROE - Shares Shorted/Prior 5.17M/4.94M Price 1.29
Gross Margin 72.68% Profit Margin -21.67% Avg. Volume 2,107,537 Target Price 4.57
Oper. Margin 5.23% Earnings Date Apr 30 Volume 1,422,371 Change -3.01%
About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals, Inc. News
04/12/24 Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
04/10/24 Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04/04/24 Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
03/12/24 Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
03/07/24 Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year
03/07/24 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript
03/06/24 Q4 2023 Rigel Pharmaceuticals Inc Earnings Call
03/06/24 Owning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),
03/05/24 Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
03/05/24 Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
02/28/24 OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
08:05 AM Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
02/22/24 Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
02/19/24 Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
01/15/24 When Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Become Profitable?
01/08/24 Rigel Pharmaceuticals Provides Business Update
01/04/24 Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
01/03/24 Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
01/03/24 Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
01/02/24 Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
RIGL Chatroom

User Image Cloud875 Posted - 23 hours ago

$RIGL Raul needs to forget the R/S with near term profitability and increased sales will get the share price much higher gaining more industry attention/ visibility. He’s gotta do better

User Image MsMaryBeth Posted - 1 day ago

$RIGL - BREAKING NEWS - Company could be announcing a reverse stock spilt soon. I don't own the stock but I did see the recent proxy & shareholders had to vote on the reverse split. Stay tuned! See attached - Best of luck Longs!

User Image GenralZod Posted - 1 day ago

$RIGL I see so many ?s with this company. Throw me some estimates for their faIr market cap. rs or no the cap should be….

User Image DosGatos Posted - 1 day ago

$RIGL Hahahaha swing ideas! $15!

User Image PennyStocksMom Posted - 1 day ago

Potential swing ideas 💡 ✅️ $RIGL recently got FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, Citigroup price raised to $4, HC Wainwright price target $15, ✅️ $APVO drop to current 52wk high due to recent offering price 1.35/share, small float, company focuses on development for breast cancer treatment, upcoming catalyst: 1) phase 1b/2 trial initiation expected 1H (first half) of 2024, recent reverse split ✅️ $NVO call 130 5/17 earnings play, mindful of position size

User Image Berakhot Posted - 1 day ago

$RIGL Daily looking more like a double-dip... what's it going to do: Dippity doo, Bibbity boo or Poppity power hour for me and you.

User Image kokooo Posted - 1 day ago

$RIGL The big picture is the company is growing revenue is up profitable Quarter three approved drugs on the market contract with Lily contract with the government. What else do you want?you guys all want it to go up but you are not buying .i do.

User Image kokooo Posted - 1 day ago

$RIGL agen root rnac all up huge after rs. now is the time to buy

User Image Berakhot Posted - 1 day ago

$RIGL so close to another move up here off bullish Hammer on 04.19. Needs to bust thru 9ema. May consolidate some more below 20ma before another move up. Looking backwards at Daily Chart, several bullish Hammers following results led to larger moves after some consolidation thru different levels. R/s is somewhat baked in. But if vote succeeds SP could take another hit before actual R/s date. Lot depends on Earnings and future guidance/positivity during call. If Raul and Crew, new CMO(improvement) come out positive & no surprises it would reassure share holders. And another question is how many Whales who recently loaded up r still in the stock? Still bullish long term. Especially when/if we get Annora off Rigel's back.

User Image noproetu Posted - 1 day ago

$RIGL lets close over $1.20

User Image MaxKlim Posted - 1 day ago

$RIGL https://meetings.asco.org/abstracts-presentations/232595

User Image MaxKlim Posted - 1 day ago

$RIGL https://meetings.asco.org/abstracts-presentations/236611

User Image Cloud875 Posted - 2 days ago

$RIGL wonder if the board of directors look at the share price as a reflection of Senior management’s performance

User Image Springsman72 Posted - 2 days ago

$RIGL Just bought 1k shares more...

User Image Pesoss Posted - 2 days ago

$RIGL 🤦🏽‍♂️🤦🏽‍♂️🤦🏽‍♂️ bruh whole market down. Gdp came in at 1.6 way lower than expected. Is the market relax

User Image JA_Animalia Posted - 2 days ago

$RIGL Rigel's agents pushing the PS below $1 to influence the proxy vote on 'blank check' RS authority for it's BOD. This organization is a snake pit of neglect, incompetence, and malfeasance. So, yeah! Let's give them the unconstrained authority to RS the shares all the way to 1:20, and then dilute them. WTAF.

User Image DosGatos Posted - 2 days ago

$RIGL yikes - below a buck on deck!

User Image Cloud875 Posted - 2 days ago

$RIGL need some great news

User Image Springsman72 Posted - 2 days ago

$RIGL Sure would be nice to get some of those high-volume purchases during regular trading hours... sighhh... always the double standard.

User Image kokooo Posted - 3 days ago

$RIGL 16:15:16 $1.13 500 16:14:32 $1.13 190 16:02:42 $1.125 216 16:01:56 $1.125 332 16:01:48 $1.125 1,073 16:01:44 $1.125 549 16:00:06 $1.125 5,777,302

User Image Bliminated Posted - 3 days ago

$RIGL 5,57m block at close.

User Image Bsbl Posted - 3 days ago

$RIGL letter was from Greg lapointe. Chairman of the board. Guess I am happy my thoughts were shared. There will at least be some conversations that some stock holders are not happy. I will still be voting no with my shares on stock split only because I have had several bad experiences with them. I will vote to approve board hoping they saw concerns and will think about moving forward

User Image Bsbl Posted - 3 days ago

$RIGL to page 50 of the Proxy Statement. RIGEL PHARMACEUTICALS, INC. 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080 650.624.1100 www.rigel.com Regarding question 8, for further information on the Company’s compensation practices and award terms, I encourage you to refer to page 59 of the Proxy Statement and other sections of the Proxy Statement discussing executive compensation and applicable metrics for determining such compensation. Regarding your other questions, we note your feedback and perspectives, which have been conveyed to the full Board. *** We appreciate your feedback as an investor and your interest in ensuring the Company’s success.

User Image Bsbl Posted - 3 days ago

$RIGL For further information, I encourage you to refer to page 54 of the Proxy Statement. Regarding questions 1 and 10, the Company follows all applicable law, rules, and regulations, including those regarding the disclosure of material non-public information and reporting to regulatory authorities. Regarding questions 2 and 4, the Reverse Stock Split Proposal is a matter separate and distinct from management and Board compensation decisions. For further information on the Company’s compensation practices, I encourage you to refer to page 59 of the Proxy Statement. Regarding question 3, if a reverse stock split is implemented, any outstanding awards under the Company’s compensation arrangements would be proportionally adjusted to appropriately reflect the terms of the reverse stock split. For further information, I encourage you to refer to p

User Image Bsbl Posted - 3 days ago

$RIGL

User Image Bsbl Posted - 3 days ago

$RIGL determined by the Board (the “Reverse Stock Split Proposal”). Such reverse splits are frequently implemented by companies trading at relatively low per share prices, and do not, by themselves, impact the market capitalization of a company. Implementing a reverse stock split may help the Company by improving the marketability of our stock, attracting and retaining employees and other service providers, and promoting greater liquidity. For further information, I encourage you to refer to page 47 of the Company’s Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”). You further note that the Board has requested that stockholders approve the adjournment of the Company’s annual meeting of stockholders to a later date, if necessary, to permit further solicitation and votes of proxies in the event there are not sufficient votes in favor of the Reverse Stock Split Proposal. Such adjournment proposals are highly typical in these types of circumstances. For further

User Image Bsbl Posted - 3 days ago

$RIGL April 24, 2024 Dear Mr. Helstrom, On behalf of the Board of Directors (the “Board”) of Rigel Pharmaceuticals, Inc. (“Rigel” or the “Company”), I want to thank you for your continued investment and interest in Rigel. I am in receipt of your email to the Board, dated April 18, 2024. The Board appreciates your feedback on the Company, including feedback on how the Company communicates with investors. As a Board and management team, we are committed to demonstrating the Company’s value to the market, and we know that an effective communication strategy with investors is key to ensuring that our strategy is understood. In that vein, I am providing responses to your questions below as they relate to the Company’s upcoming annual meeting of stockholders. As you note, the Board has requested that stockholders approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock, if and when

User Image novumcarpediem Posted - 3 days ago

$RIGL

User Image flcountryboy Posted - 3 days ago

$RIGL Plus, if you look at those officer stock sale dates, they were probably selling enough shares to cover tax liabilities, plus padding. Not like anyone fully divested their share ownership.

User Image Berakhot Posted - 3 days ago

$RIGL Resulting outcome of R/s April fools joke Daily Chart... Higher high of 1.57, then higher Low(red circle), then return to up trend before the Yellow line for April fools dump. Currently rebound line off an area of support attempting to break thru 8ema(pink step line)...

Analyst Ratings
Citigroup Buy Mar 7, 24
Cantor Fitzgerald Neutral Mar 6, 24
HC Wainwright & Co. Buy Mar 6, 24
B. Riley Securities Neutral Mar 6, 24
HC Wainwright & Co. Buy Feb 22, 24
HC Wainwright & Co. Buy Jan 4, 24
HC Wainwright & Co. Buy Dec 8, 23
HC Wainwright & Co. Buy Aug 2, 23
HC Wainwright & Co. Buy May 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Santos David A EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 02 Sell 1.14 14,519 16,552 349,093 02/06/24
Schorno Dean L EVP & Chief Financia.. EVP & Chief Financial Officer Feb 02 Sell 1.13 12,628 14,270 402,891 02/06/24
RODRIGUEZ RAUL R CEO, President CEO, President Feb 02 Sell 1.14 52,894 60,299 2,036,629 02/06/24
RODRIGUEZ RAUL R CEO, President CEO, President Jun 09 Buy 0.6884 1,000,000 688,400 1,391,776 06/13/22